JOHNSON & JOHNSON
`
`FORM 10-K
`(Annual Report)
`
`Filed 2/21/2007 For Period Ending 12/31/2006
`
`Address
`
`Telephone
`CIK
`Industry
`Sector
`
`Fiscal Year
`
`ON E JOHNSON & JOHNSON PLZ
`NEW BRUNSWICK, New Jersey 08933
`732-524-2455
`0000200406
`Major Drugs
`Healthcare
`12/31
`
`Powwed By EDGA.Rbnline
`http://'www.edgar-online.coml
`Cl Copyright 2006. All Rights Resef'ied.
`DJslrlbution and use ol lhis document r1!'61ncled under EDGAR Onllnes Terms of Use.
`
`Eye Therapies Exhibit 2076, 1 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`Eye Therapies Exhibit 2076, 2 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`
`UNITED STATES
`SECURITIES AND EXCHANGE COMMISSION
`Washington, D.C. 20549
`
`FORM 10-K
`
`
`For the fiscal year ended December 31, 2006
`
`ANNUAL REPORT PURSUANT TO SECTION 13 OF
`THE SECURITIES EXCHANGE ACT OF 1934
`
`Commission file number 1-3215
`
`JOHNSON & JOHNSON
`
`
`
`
`
`
`
`(Exact name of registrant as specified in its charter)
`
`
`
`
`New Jersey
`(State of
`Incorporation)
`
`One Johnson & Johnson Plaza
`New Brunswick, New Jersey
`(Address of principal executive offices)
`
`
`
`
`
`
`22-1024240
`(I.R.S. Employer
`Identification No.)
`
`08933
`(Zip Code)
`
`Registrant’s telephone number, including area code: (732) 524-0400
`
`SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
`
`
`
`Title of each class
`
`Name of each exchange on which registered
`
`Common Stock, Par Value $1.00
`
`
`
`New York Stock Exchange
`
` Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No
`
` Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes
` No 
`
` Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
`Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
`subject to such filing requirements for the past 90 days. Yes  No
`
` Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
`contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this
`Form 10-K or any amendment to this Form 10-K. 
`
` Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.
`Large accelerated filer  Accelerated filer Non-accelerated filer
`
` Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No 
`
` The aggregate market value of the common stock held by non-affiliates (computed by reference to the price at which the common stock
`was last sold) as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $175 billion.
`
` On February 16, 2007 there were 2,894,082,681 shares of Common Stock outstanding.
`
`Eye Therapies Exhibit 2076, 3 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`Parts I, II and III:
`Parts I and III:
`
`DOCUMENTS INCORPORATED BY REFERENCE
`
`
`Portions of registrant’s annual report to shareholders for fiscal year 2006 (the “Annual Report”).
`Portions of registrant’s proxy statement for its 2007 annual meeting of shareholders filed within 120 days
`after the close of the registrant’s fiscal year (the “Proxy Statement”).
`
`
`
`
`
`Eye Therapies Exhibit 2076, 4 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`
`
`
`
`
`
`Item
`
`
`
`
`
`PART I
`
` 1.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 1A.
`
` 1B.
` 2.
` 3.
` 4.
`
`
`
` 5.
`
` 6.
` 7.
`
` 7A.
`
` 8.
` 9.
`
` 9A.
`
` 9B.
`
` 10.
` 11.
` 12.
` 13.
` 14.
`
` 15.
`
`
`
`
`
`
`
`
` Business
` General
` Segments of Business
` Consumer
` Pharmaceutical
` Medical Devices and Diagnostics
` Geographic Areas
` Raw Materials
` Patents and Trademarks
` Seasonality
` Competition
` Research and Development
` Environment
` Regulation
` Available Information
` Risk Factors
` Unresolved Staff Comments
` Properties
` Legal Proceedings
` Submission of Matters to a Vote of Security Holders
` Executive Officers of the Registrant
`
`PART II
`Market for the Registrant’s Common Equity, Related Stockholder Matters and
`Issuer Purchases of Equity Securities
`
` Selected Financial Data
`Management’s Discussion and Analysis of Financial Condition and Results of
`Operation
`
` Quantitative and Qualitative Disclosures About Market Risk
` Financial Statements and Supplementary Data
` Changes in and Disagreements With Accountants on Accounting and Financial
`Disclosure
` Controls and Procedures
` Other Information
`
`
`PART III
` Directors, Executive Officers and Corporate Governance
` Executive Compensation
` Security Ownership of Certain Beneficial Owners and Management and
`Related Stockholder Matters
` Certain Relationships and Related Transactions, and Director Independence
` Principal Accounting Fees and Services
`
`PART IV
` Exhibits, Financial Statement Schedules
` Signatures
` Report of Independent Registered Public Accounting Firm on Financial
`Statement Schedule
` Exhibit Index
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page
`
` 1
` 1
` 1
` 1
` 1
` 2
` 2
` 2
` 2
` 3
` 3
` 3
` 3
` 3
` 4
` 4
` 4
` 4
` 5
` 6
` 6
`
` 7
` 8
`
` 8
` 8
` 8
` 8
` 9
`
` 10
`
` 10
`
`
` 10
`
` 11
`
`
` 11
`
` 12
`
` 12
`
`
` 14
` 16
`
`
` 17
`
`Eye Therapies Exhibit 2076, 5 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`
`Item 1. BUSINESS
`
`General
`
`PART I
`
` Johnson & Johnson and its subsidiaries have approximately 122,200 employees worldwide engaged in the research and development,
`manufacture and sale of a broad range of products in the health care field. Johnson & Johnson has more than 250 operating companies
`conducting business in virtually all countries of the world. Johnson & Johnson’s primary focus has been on products related to human health
`and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
`
` The Company’s structure is based on the principle of decentralized management. The Executive Committee of Johnson & Johnson is the
`principal management group responsible for the operations and allocation of the resources of the Company. This Committee oversees and
`coordinates the activities of the Consumer, Pharmaceutical and Medical Devices and Diagnostics business segments. Each subsidiary within
`the business segments is, with some exceptions, managed by citizens of the country where it is located.
`
`Segments of Business
`
` Johnson & Johnson is organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. Additional
`information required by this item is incorporated herein by reference to the narrative and tabular (but not the graphic) descriptions of segments
`and operating results under “Management’s Discussion and Analysis of Results of Operations and Financial Condition” on pages 38 through 49
`and Note 11 “Segments of Business and Geographic Areas” under “Notes to Consolidated Financial Statements” on page 61 of the Annual
`Report, filed as Exhibit 13 to this Report on Form 10-K.
`
`Consumer
`
` The Consumer segment includes a broad range of products used in the baby and kids care, skin care, oral care, wound care and women’s
`health care fields, as well as nutritional and over-the-counter pharmaceutical products. Major brands include AVEENO ® skin care products;
`BAND-AID ® Brand Adhesive Bandages; CAREFREE ® Pantiliners; CLEAN & CLEAR ® teen skin care products; JOHNSON’S ® Baby and
`Adult lines of products; MOTRIN ® IB ibuprofen products; NEUTROGENA ® skin and hair care products; RoC ® skin care products; PEPCID
`® AC Acid Controller from Johnson & Johnson • Merck Consumer Pharmaceuticals Co.; REMBRANDT ® Brand of oral care products;
`SPLENDA ® No Calorie Sweetener; STAYFREE ® sanitary protection products; and the broad family of TYLENOL ® acetaminophen
`products. These products are marketed principally to the general public and sold both to wholesalers and directly to independent and chain
`retail outlets throughout the world.
`
` In the fiscal fourth quarter of 2006, the Company completed the acquisition of the Consumer Healthcare business of Pfizer Inc. comprising
`products related to self-medications for oral care, upper-respiratory health, tobacco dependence, gastrointestinal health, skin care, eye care and
`hair growth. Major brands of the Consumer Healthcare business of Pfizer Inc. include LISTERINE ® oral care products, the NICORETTE ®
`line of smoking cessation treatments, and SUDAFED ® cold, flu and allergy products.
`
`Pharmaceutical
`
` The Pharmaceutical segment includes products in the following therapeutic areas: anti-fungal, anti-infective, cardiovascular, contraceptive,
`dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic (central nervous system),
`urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use by the
`general public. Key products in the Pharmaceutical segment include: RISPERDAL ® (risperidone) and RISPERDAL ® CONSTA ® (risperidone
`long-acting injection), for treatment of the symptoms of schizophrenia; PROCRIT ® (Epoetin alfa, sold outside the U.S. as EPREX ® ), a
`biotechnology-derived product that stimulates red blood cell production; REMICADE ® (infliximab), a monoclonal antibody therapy indicated
`to treat the symptoms of Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, chronic severe plaque psoriasis and use in
`the treatment of rheumatoid arthritis; TOPAMAX ® (topiramate), an anti-epileptic and migraine prevention treatment; LEVAQUIN ®
`(levofloxacin) and FLOXIN ® (ofloxacin), both in the anti-infective field; DURAGESIC ® /Fentanyl
`
`Eye Therapies Exhibit 2076, 6 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`
`Transdermal (fentanyl transdermal system, sold outside the U.S. as DUROGESIC ® ), a treatment for chronic pain that offers a novel delivery
`system; ORTHO EVRA ® (norelgestromin/ethinyl estradiol transdermal system), the first contraceptive patch approved by the U.S. Food and
`Drug Administration (“FDA”) and ORTHO TRI-CYCLEN ® LO (norgestimate/ethinyl estradiol), a low dose oral contraceptive; CONCERTA
`® (methylphenidate HCl) a product for the treatment of attention deficit hyperactivity disorder; and NATRECOR ® (nesiritide), a product for
`the treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
`
`Medical Devices and Diagnostics
`
` The Medical Devices and Diagnostics segment includes a broad range of products distributed to wholesalers, hospitals and retailers, used
`principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include
`Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction and spinal care products; Ethicon’s wound care
`and women’s health products; Ethicon Endo-Surgery’s minimally invasive surgical products; LifeScan’s blood glucose monitoring and insulin
`delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products and Vision Care’s disposable contact lenses. Distribution to
`these health care professional markets is done both directly and through surgical supply and other dealers.
`
`Geographic Areas
`
` The international business of Johnson & Johnson is conducted by subsidiaries located in 56 countries outside the United States, which are
`selling products in virtually all countries throughout the world. The products made and sold in the international business include many of those
`described above under “Business — Consumer,” “— Pharmaceutical” and “— Medical Devices and Diagnostics.” However, the principal
`markets, products and methods of distribution in the international business vary with the country and the culture. The products sold in
`international business include not only those which were developed in the United States, but also those which were developed by subsidiaries
`abroad.
`
` Investments and activities in some countries outside the United States are subject to higher risks than comparable U.S. activities because
`the investment and commercial climate is influenced by restrictive economic policies and political uncertainties.
`
`Raw Materials
`
` Raw materials essential to Johnson & Johnson’s operating companies’ businesses are generally readily available from multiple sources.
`
`Patents and Trademarks
`
` Johnson & Johnson has made a practice of obtaining patent protection on its products and processes where possible. Johnson & Johnson
`owns or is licensed under a number of patents relating to its products and manufacturing processes, which in the aggregate are believed to be of
`material importance in the operation of its business. Sales of the Company’s two largest products, RISPERDAL ® /RISPERDAL ® CONSTA ®
`and PROCRIT ® /EPREX ® , accounted for approximately 8% and 6% of Johnson & Johnson’s total revenues, respectively, for fiscal 2006.
`Accordingly, the patents related to these products are believed to be material to Johnson & Johnson as a whole.
`
` During 2004, 2005 and 2006, DURAGESIC ® /Fentanyl Transdermal (fentanyl transdermal system) lost its basic patent protection and is
`subject to generic competition in the United States and certain international markets and EPREX ® (Epoetin alfa) lost its basic patent protection
`and is subject to generic competition in international markets. DURAGESIC ® /Fentanyl Transdermal sales declined by 18.3% to $1.3 billion in
`2006 as compared to 2005, due to the impact of generic competition. Regarding EPREX ® , generic competition will be limited in the near term
`due to the lack of approved generic compounds. Combined sales of DURAGESIC ® /Fentanyl Transdermal and EPREX ® accounted for
`approximately 5% of Johnson & Johnson’s worldwide sales in 2006. The only material patents scheduled to expire within the next two years
`are related to
`
`2
`
`Eye Therapies Exhibit 2076, 7 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`
`
`
`RISPERDAL ® , which is scheduled to expire in the United States in December 2007, and TOPAMAX ® , which is scheduled to expire in the
`United States in September 2008. The Company has submitted data to the FDA in order to obtain a pediatric extension for RISPERDAL ® ,
`which, if approved, would grant exclusivity in the United States through June 2008. The TOPAMAX ® patent also carries the possibility of a
`pediatric extension in the United States, which, if obtained, would grant exclusivity in the United States until March 2009.
`
` Johnson & Johnson has made a practice of selling its products under trademarks and of obtaining protection for these trademarks by all
`available means. Johnson & Johnson’s trademarks are protected by registration in the United States and other countries where its products are
`marketed. Johnson & Johnson considers these trademarks in the aggregate to be of material importance in the operation of its business.
`
`Seasonality
`
` Worldwide sales do not reflect any significant degree of seasonality; however, spending has been heavier in the fourth quarter of each year
`than in other quarters. This reflects increased spending decisions, principally for advertising and research grants.
`
`Competition
`
` In all of their product lines, Johnson & Johnson companies compete with companies both large and small, located throughout the world.
`Competition is strong in all product lines without regard to the number and size of the competing companies involved. Competition in research,
`involving the development and the improvement of new and existing products and processes, is particularly significant. The development of
`new and improved products is important to Johnson & Johnson’s success in all areas of its business. This competitive environment requires
`substantial investments in continuing research and multiple sales forces. In addition, the development and maintenance of customer acceptance
`of the products of Johnson & Johnson’s consumer businesses involves significant expenditures for advertising and promotion.
`
`Research and Development
`
` Research activities represent a significant part of Johnson & Johnson’s business. Major research facilities are located not only in the United
`States but also in Australia, Belgium, Brazil, Canada, China, France, Germany, India, Japan, the Netherlands, Singapore and the United
`Kingdom. The costs of worldwide Company-sponsored research activities relating to the development of new products, improvement of
`existing products, technical support of products and compliance with governmental regulations for the protection of consumers and patients,
`excluding in-process research and development charges, amounted to $7,125 million, $6,462 million and $5,344 million for fiscal years 2006,
`2005 and 2004, respectively. These costs are charged directly to income in the year in which incurred.
`
`Environment
`
` Johnson & Johnson companies are subject to a variety of federal, state and local environmental protection measures. Johnson & Johnson
`believes that its operations comply in all material respects with applicable environmental laws and regulations. Johnson & Johnson’s
`compliance with these requirements did not, during the past year, and is not expected to, have a material effect upon its capital expenditures,
`cash flows, earnings or competitive position.
`
`Regulation
`
` Most of Johnson & Johnson’s business is subject to varying degrees of governmental regulation in the countries in which operations are
`conducted, and the general trend is toward increasingly stringent regulation. In the United States, the drug, device, diagnostics and cosmetic
`industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing,
`advertising, labeling and safety reporting. The exercise of broad regulatory powers by the FDA continues to result in increases in the amounts
`of testing and documentation required for FDA clearance of new drugs and devices
`
`3
`
`Eye Therapies Exhibit 2076, 8 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`
`and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the United
`States.
`
` The costs of human health care have been and continue to be a subject of study, investigation and regulation by governmental agencies and
`legislative bodies around the world. In the United States, attention has been focused on drug prices and profits and programs that encourage
`doctors to write prescriptions for particular drugs or recommend, use or purchase particular medical devices. Payers have become a more potent
`force in the market place and increased attention is being paid to drug and medical device pricing, appropriate drug and medical device
`utilization and the quality and costs of health care. In the United States, implementation of the Medicare Prescription Drug, Improvement and
`Modernization Act of 2003 and the Deficit Reduction Act of 2005 may cause uncertainty in reimbursement levels in certain product segments.
`
` The regulatory agencies under whose purview Johnson & Johnson companies operate have administrative powers that may subject those
`companies to such actions as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, Johnson &
`Johnson’s operating companies may deem it advisable to initiate product recalls.
`
` In addition, business practices in the health care industry have come under increased scrutiny, particularly in the United States, by
`government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal
`penalties.
`
`Available Information
`
` Copies of Johnson & Johnson’s quarterly reports on Form 10-Q, annual report on Form 10-K and current reports on Form 8-K, and any
`amendments to the foregoing, will be provided without charge to any shareholder submitting a written request to the Secretary at the principal
`executive offices of the Company or by calling 800-328-9033. All of the Company’s Securities and Exchange Commission (“SEC”) filings are
`also available on the Company’s Web site at www.investor.jnj.com/governance , as soon as reasonably practicable after having been
`electronically filed or furnished to the SEC. All SEC filings are also available at the SEC’s Web site at www.sec.gov . In addition, the Charters
`of the Audit Committee, the Compensation & Benefits Committee and the Nominating & Corporate Governance Committee of the Board of
`Directors and the Company’s Principles of Corporate Governance, Policy on Business Conduct for employees and Code of Business Conduct
`& Ethics for Members of the Board of Directors and Executive Officers are available at the www.investor.jnj.com/governance Web site address
`and will be provided without charge to any shareholder submitting a written request, as provided above.
`
`Item 1A. RISK FACTORS
`
` Not applicable.
`
`Item 1B. UNRESOLVED STAFF COMMENTS
`
` Not applicable.
`
`Item 2. PROPERTIES
`
` Johnson & Johnson and its worldwide subsidiaries operate 148 manufacturing facilities occupying approximately 22.6 million square feet
`of floor space.
`
`4
`
`Eye Therapies Exhibit 2076, 9 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`
` The manufacturing facilities are used by the industry segments of Johnson & Johnson’s business approximately as follows:
`
`
`
`
`Square Feet
`(in thousands)
`
`Segment
`
`Consumer
`Pharmaceutical
`Medical Devices and Diagnostics
`
` Worldwide Total
`
`
`
`
`
`
`
`
`
` 8,410
` 6,743
` 7,417
`
` 22,570
`
`
`
`
`-
`
` Within the United States, 7 facilities are used by the Consumer segment, 14 by the Pharmaceutical segment and 42 by the Medical Devices
`and Diagnostics segment. Johnson & Johnson’s manufacturing operations outside the United States are often conducted in facilities that serve
`more than one segment of the business.
`
` The locations of the manufacturing facilities by major geographic areas of the world are as follows:
`
`
`
`
`
`
`Number
`of
`Facilities
`
`Geographic Area
`
`
`
`
`
`
`
`
`
`Square Feet
`(in thousands)
`
`United States
`Europe
`Western Hemisphere, excluding U.S.A.
`Africa, Asia and Pacific
`
` Worldwide Total
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 63
` 37
` 16
` 32
`
` 148
`
`
`
`
`-
`
`
`
`
`
`
`
`
`
`
`
`
`
` 7,448
` 8,667
` 3,026
` 3,429
`
` 22,570
`
`
`
`
`-
`
` In addition to the manufacturing facilities discussed above, Johnson & Johnson maintains numerous office and warehouse facilities
`throughout the world. Research facilities are also discussed in Item 1 under “Business — Research.”
`
` Johnson & Johnson generally seeks to own its manufacturing facilities, although some, principally in locations abroad, are leased. Office
`and warehouse facilities are often leased.
`
` Johnson & Johnson’s properties are maintained in good operating condition and repair and are well utilized.
`
` For information regarding lease obligations, see Note 4 “Rental Expense and Lease Commitments” under “Notes to Consolidated Financial
`Statements” on page 57 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K. Segment information on additions to property,
`plant and equipment is contained in Note 11 “Segments of Business and Geographic Areas” under “Notes to Consolidated Financial
`Statements” on page 61 of the Annual Report, filed as Exhibit 13 to this Report on Form 10-K.
`
`Item 3. LEGAL PROCEEDINGS
`
` The information set forth in Note 18 “Legal Proceedings” under “Notes to Consolidated Financial Statements” on pages 69 through 74 of
`the Annual Report is incorporated herein by reference and filed as Exhibit 13 to this Report on Form 10-K.
`
` The Company or its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response,
`Compensation and Liability Act, commonly known as Superfund, and comparable state laws, in which the primary relief sought is the cost of
`past and future remediation. While it is not feasible to predict or determine the outcome of these proceedings, in the opinion of the Company,
`such proceedings would not have a material adverse effect on the results of operations, cash flows or financial position of the Company.
`
`5
`
`Eye Therapies Exhibit 2076, 10 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`
`Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
`
` Not applicable.
`
`Executive Officers of the Registrant
`
` Listed below are the executive officers of Johnson & Johnson as of February 21, 2007, each of whom, unless otherwise indicated below,
`has been an employee of the Company or its affiliates and held the position indicated during the past five years. There are no family
`relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other
`person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors, the executive officers are elected
`by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or removal.
`
` Information with regard to the directors of the Company, including those of the following executive officers who are directors, is
`incorporated herein by reference to the material captioned “Election of Directors” in the Proxy Statement.
`
`
`
`
`
`Age
`
`Position
`
`Name
`
`Dominic J. Caruso
`
`Robert J. Darretta
`Russell C. Deyo
`
`Kaye I. Foster-Cheek
`Colleen A. Goggins
`
`Per A. Peterson, M.D., Ph.D.
`
`Christine A. Poon
`Joseph C. Scodari
`
`Nicholas J. Valeriani
`
`William C. Weldon
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Member, Executive Committee; Vice President, Finance; Chief Financial
` 49
`Officer(a)
`
` 60 Vice Chairman, Board of Directors; Member, Executive Committee(b)
`Member, Executive Committee; Vice President, General Counsel and
` 57
`Chief Compliance Officer(c)
`
` 48 Member, Executive Committee; Vice President, Human Resources(d)
`Member, Executive Committee; Worldwide Chairman, Consumer &
` 52
`Personal Care Group(e)
`
` 62 Member, Executive Committee; Chairman, Research & Development,
`Pharmaceuticals Group(f)
` 54 Vice Chairman, Board of Directors; Member, Executive Committee
` 54 Member, Executive Committee; Worldwide Chairman, Pharmaceuticals
`Group(g)
`Member, Executive Committee; Worldwide Chairman, Medical Devices
` 50
`and Diagnostics Group(h)
`
` 58 Chairman, Board of Directors; Chairman, Executive Committee; Chief
`Executive Officer
`
`(a) Mr. D. J. Caruso joined the Company in October 1999 when the Company acquired Centocor, Inc. At the time of that acquisition, he had
`been Vice President, Finance of Centocor. Mr. Caruso was named Vice President, Finance of Ortho-McNeil Pharmaceutical, Inc. in 2001
`and Vice President, Group Finance of the Company’s Medical Devices and Diagnostics Group in May 2003. In December 2005,
`Mr. Caruso was named Vice President of the Company’s Group Finance organization. Mr. Caruso became a Member of the Executive
`Committee and Vice President, Finance and Chief Financial Officer on January 1, 2007.
`
`
`(b) Mr. R. J. Darretta joined the Company in 1968 and held several accounting and finance positions before becoming Managing Director of
`Ethicon Italy in 1985. He was named President of IOLAB Corporation in 1988 and in 1995 became Treasurer of the Company.
`Mr. Darretta was named Vice President, Finance and Chief Financial Officer and appointed to the Executive Committee in 1997. He was
`appointed Executive Vice President in 2002 and Vice Chairman, Board of Directors in January 2004. Mr. Darretta retired from the position
`of Chief Financial Officer as of December 31, 2006 and plans to retire from the Company in 2007.
`
`6
`
`Eye Therapies Exhibit 2076, 11 of 128
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`
`
`(c) Mr. R. C. Deyo joined the Company in 1985 and became Associate General Counsel in 1991. He became a Member of the Executive
`Committee and Vice President, Administration, in 1996 and Vice President, General Counsel and Chief Compliance Officer in April 2004.
`
`(d) Ms. K. I. Foster-Cheek joined the Company in 2003 as Vice President, Human Resources, for the Johnson & Johnson Consumer Products
`Companies. In March 2004, she was named Vice President, Human Resources, for the Consumer & Personal Care Group and was named
`a member of the Human Resources Leadership Team and the Consumer & Personal Care Group Operating Committee. Ms. Foster-Cheek
`became a Member of the Executive Committee and Vice President, Human Resources, for the Company in January 2005. Prior to joining
`the Company, Ms. Foster-Cheek served in various human resources management positions with Pfizer Inc. for 13 years, most recently
`supporting its pharmaceutical business in Japan, Asia, Africa, Middle East and Latin America.
`
`(e) Ms. C. A. Goggins joined the Company in 1981 and held various positions before becoming President of Personal Products Company in
`1994. She was named President of Johnson & Johnson Consumer Products Company in 1995 and Company Group Chairman, North
`America, Johnson & Johnson Consumer Products in 1998. Ms. Goggins became a Member of the Executive Committee and Worldwide
`Chairman, Consumer & Personal Care Group, in 2001.
`
`
`(f) Dr. P. A. Peterson joined the Company in 1994 as Vice President, Drug Discovery, of The R.W. Johnson Pharmaceutical Research
`Institute. He was named Group Vice President of The Pharmaceutical Research Institute in April 1998 and its President in November 1998.
`In 2000, Dr. Peterson was named Chairman, Research & Development, Pharmaceuticals Group. Dr. Peterson became a Member of the
`Executive Committee in 2001. He plans to retire from the Company in 2007.
`
`
`(g) Mr. J. C. Scodari joined the Company in 1999 as President of Centocor when the Company acquired Centocor. At the time of that
`acquisition, he had been the President and Chief Operating Officer of Centocor and a member of Centocor’s Board of Directors since
`December 1997. In March 2001, he was named Company Group Chairman for the North American pharmaceutical business, and became a
`member of the Pharmaceuticals Group Operating Committee. In March 2003, Mr. Scodari was named Company Group Chairman,
`Biopharmaceutical Businesses. Mr. Scodari was named Worldwide Chairman, Pharmaceuticals Group, and became a Member of the
`Executive Committee in March 2005.
`
`(h) Mr. N. J. Valeriani joined the Company in 1978 and held various positions before becoming President of Ethicon Endo-Surgery, Inc. in
`1997. In January 2001 he was named Company Group Chairman for Ethicon Endo-Surgery with additional responsibility for the
`Johnson & Johnson Medical Products Medical Devices and Diagnostics business in Canada. He became Worldwide Franchise Chairman
`for the DePuy Franchise in 2002. Mr. Valeriani became a Member of the Executive Committee and Vice President, Human Resources, in
`September 2003. In February 2004 he assumed additional responsibilities as Worldwide Chairman, Diagnostics. In January 2005,
`Mr. Valeriani was appointed Worldwide Chairman, Cardiovascular Devices and Diagnostics and relinquished his Human Resources
`responsibilities. He became Worldwide Chairman, Medical Devices and Diagnostic